Business Wire·Nov 9, 2026, 10:50 AM ET

Alnylam Announces Five-Year HELIOS-B Data Demonstrating Sustained Benefit of AMVUTTRA® (vutrisiran) in ATTR-CM

New data presented at the 2026 American Heart Association Scientific Sessions show AMVUTTRA (vutrisiran) provides sustained benefits in mortality, cardiovascular events, quality of life, & cardiac biomarkers over 60 months.
Continuous AMVUTTRA treatment resulted in a 48% lower risk of all-cause mortality & recurrent cardiovascular events in the monotherapy population & a 41% lower risk in the overall population compared to delayed initiation.
Early treatment initiation with AMVUTTRA preserved quality of life scores (KCCQ-OS) & maintained greater stability in cardiac biomarkers like NT-proBNP & troponin I relative to delayed starts.
Post hoc cardiopulmonary exercise testing demonstrated that AMVUTTRA preserved exercise capacity (peak oxygen uptake) & favorable cardiopulmonary response components compared to placebo over two years.
Patients receiving AMVUTTRA alongside baseline tafamidis experienced a 23% reduction in recurrent cardiovascular events compared to those on tafamidis alone who later initiated AMVUTTRA.
The safety profile of AMVUTTRA remained consistent through 60 months with no new safety signals, though treatment requires recommended daily allowance vitamin A supplementation due to reduced serum levels.
AMVUTTRA is the only TTR silencer approved globally for both hereditary transthyretin-mediated amyloidosis polyneuropathy (hATTR-PN) & cardiomyopathy (ATTR-CM).